ClinicalTrials.gg
CompletedNCT03669588ADAPTUpdated Feb 8, 2022Results posted

An Efficacy and Safety Study of ARGX-113 in Patients With Myasthenia Gravis Who Have Generalized Muscle Weakness

A Phase 3 interventional study of ARGX-113 and Placebo in Generalized Myasthenia Gravis, sponsored by argenx. Completed at 66 sites in 16 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-02-08.

Sponsored by argenx · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
167
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 20 studies testing efgartigimod alfa in Myasthenia Gravis — 11 open to participants now, 14 under way, 7 of them phase 3. efgartigimod alfa · Myasthenia Gravis.

Enrollment
2nd of 20
167 · median 55
Started
2018
the only one that year
Phase 3
10 of 20
3 open now
Registered
2nd of 20
by date
Lead sponsor
12 of 20
argenx

Among the 20 studies testing efgartigimod alfa in Myasthenia Gravis, this one is the 2nd largest by enrollment, is the only one that started in 2018, is one of 10 in phase 3, and was the 2nd registered.

Myasthenia Gravis

331 studies on the registry are indexed under Myasthenia Gravis; 145 are open to participants now.

Browse Myasthenia Gravis studies →

Open to participants now

11 of the 20 studies testing efgartigimod alfa in Myasthenia Gravis are open now, in 12 countries. Recruiting first, the newest first:

6 more — sign in →

By country, each count listing its studies:

All 11 open studies →

About efgartigimod alfa

efgartigimod alfa: first FDA approval 2021 (VYVGART), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 104 Myasthenia Gravis studies recruiting now, 64 (62%) set no upper age limit and 23 (22%) stop at 75 or younger; 16 take children under 18; 13 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies testing efgartigimod alfa in Myasthenia Gravis, or all of them as a file.
02

Study summary

A randomized, double-blind, placebo controlled, multicenter Phase 3 trial to evaluate the efficacy, safety, tolerability, quality of life and impact on normal daily activities of ARGX-113 in patients with gMG.

03

Conditions studied

  • Generalized Myasthenia Gravis

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients with the ability to understand the requirements of the trial, provide written , and comply with the trial protocol procedures.
  2. Male or female patients aged ≥ 18 years.
  3. Diagnosis of MG with generalized muscle weakness meeting the clinical criteria for diagnosis of MG as defined by the Myasthenia Gravis Foundation of America (MGFA) class II, III, IVa and IVb.

Other, more specific inclusion criteria are defined in the protocol

Exclusion criteria

Exclusion Criteria:

  1. Pregnant and lactating women, and those intending to become pregnant during the trial or within 90 days after the last dosing.
  2. Male patients who are sexually active and do not intend to use effective methods of during the trial or within 90 days after the last dosing or male patients who plan to donate sperm during the trial or within 90 days after the last dosing.
  3. MGFA Class I and V patients.
  4. Patients with worsening muscle weakness secondary to concurrent infections or medications.
  5. Patients with known seropositivity or who test positive for an active viral infection at Screening with:

    • Virus (HBV) (except patients who are seropositive because of HBV vaccination)
    • Virus (HCV)
    • (HIV)

Other, more specific exclusion criteria are further defined in the protocol.

Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
167 participants (actual)

Study arms

  • Experimental
    ARGX-113

    Biological: ARGX-113

  • Placebo comparator
    Placebo

    Biological: Placebo

Interventions

  • BiologicalARGX-113

    Intravenous administration of ARGX-113

    Also known as: efgartigimod

  • BiologicalPlacebo

    Intravenous administration of placebo

06

What researchers measure

Primary outcomes

  1. Percentage of MG-ADL Responders During Cycle 1 (C1); Analyzed in the AChR-Ab Seropositive Population

    The MG-ADL is an 8-item patient-reported scale to assess MG symptoms and their effects on daily activities. The scale comprises 2 items on daily life activities and 6 items on symptoms. The MG-ADL total score range is 0-24, with higher scores indicative of greater disease severity. A patient was considered an MG-ADL responder during C1 if there was a reduction of ≥2 points on the MG-ADL total score (compared to baseline of C1 \[C1B\]) for ≥4 consecutive weeks with the first reduction occurring no later than 1 week after the last infusion of IMP in C1.

    Time frame: Baseline up to Day 63 (end of TC1)

Secondary outcomes

  1. Percentage of Quantitative Myasthenia Gravis (QMG) Responders During C1; Analyzed in the AChR-Ab Seropositive Population

    The QMG scale quantifies disease severity based on impairments of body functions and structures as defined by the International Classification of Disability and Health. The QMG scale consists of 13 items that measure endurance or fatigability, and accounts for fluctuations in disease state. The QMG total score range is 0-39, with higher scores indicative of greater disease severity. A patient was considered a QMG responder during C1 if there was a reduction of ≥3-points on the QMG total score (compared to C1B) for ≥4 consecutive weeks with the first reduction occurring no later than 1 week after the last infusion of IMP in C1.

    Time frame: Baseline up to Day 63 (end of TC1)

  2. Percentage of MG-ADL Responders During C1; Analyzed in the Overall Population

    The percentage of MG-ADL responders during C1 in the overall population is reported for this secondary end point; percentage of MG-ADL responders during C1 in the AChR-Ab seropositive population is reported previously as a primary end point.

    Time frame: Baseline up to Day 63 (end of TC1)

  3. Percentage of Time That Patients Had a Clinically Meaningful Improvement (CMI) in MG-ADL Total Score up to and Including Day 126; Analyzed in the AChR-Ab Seropositive Population

    An MG-ADL CMI was defined as a reduction of ≥2 points on the total MG-ADL score compared to study entry baseline (SEB).

    Time frame: Baseline up to Day 126

  4. Time From Week 4 to Qualify for Retreatment; Analyzed in the AChR-Ab Seropositive Population

    Time to qualify for retreatment was defined as time from the Week 4 assessment until the first visit with a \<2-point reduction compared to SEB in the MG-ADL total score and MG-ADL total score ≥5 points with \>50% of the total score attributable to nonocular symptoms.

    Time frame: Week 4 up to Day 182 (end of study [EoS])

  5. Percentage of Early MG-ADL Responders During C1; Analyzed in the AChR-Ab Seropositive Population

    A patient was considered an early MG-ADL responder during C1 if there was a reduction of ≥2 points on the MG-ADL total score (compared to C1B) for ≥4 consecutive weeks with the first reduction occurring no later than Week 2 (ie, after 1 or maximum 2 infusions of IMP in C1).

    Time frame: Baseline up to Day 63 (end of TC1)

07

Results

Posted Feb 8, 2022

Participant flow

Study was conducted in generalized myasthenia gravis (gMG) patients at 56 sites worldwide. Patients were randomized 1:1 within each stratum (Japanese/non-Japanese, acetylcholine receptor-antibody \[AChR-Ab\] status and standard of care \[SoC; ie, concomitant gMG treatment\]) to receive ARGX-113 intravenous (IV) 10 milligrams/kilogram (mg/kg) or placebo, in addition to SoC. Patients completing the study were eligible to roll over into a follow-up study ARGX-113-1705.

Participant flow — Overall Study
MilestoneARGX-113Placebo
Started8483
Completed8076
Not completed47
Withdrew: Adverse event10
Withdrew: Physician decision01
Withdrew: Protocol violation10
Withdrew: Sponsor decision11
Withdrew: Withdrawal by subject14
Withdrew: Rescue therapy needed01

Outcome measures

PrimaryPercentage of MG-ADL Responders During Cycle 1 (C1); Analyzed in the AChR-Ab Seropositive Population

The MG-ADL is an 8-item patient-reported scale to assess MG symptoms and their effects on daily activities. The scale comprises 2 items on daily life activities and 6 items on symptoms. The MG-ADL total score range is 0-24, with higher scores indicative of greater disease severity. A patient was considered an MG-ADL responder during C1 if there was a reduction of ≥2 points on the MG-ADL total score (compared to baseline of C1 \[C1B\]) for ≥4 consecutive weeks with the first reduction occurring no later than 1 week after the last infusion of IMP in C1.

Time frame:
Baseline up to Day 63 (end of TC1)
Reported as:
Number · percentage of patients
Percentage of MG-ADL Responders During Cycle 1 (C1); Analyzed in the AChR-Ab Seropositive Population
percentage of patientsARGX-113Placebo
Percentage of MG-ADL Responders During Cycle 1 (C1); Analyzed in the AChR-Ab Seropositive Population67.729.7
Statistical analysis
  • ARGX-113 vs Placebo · Regression, Logistic · p = <0.0001 · Odds ratio (or): 4.951 · 95% CI 2.213 to 11.528
SecondaryPercentage of Quantitative Myasthenia Gravis (QMG) Responders During C1; Analyzed in the AChR-Ab Seropositive Population

The QMG scale quantifies disease severity based on impairments of body functions and structures as defined by the International Classification of Disability and Health. The QMG scale consists of 13 items that measure endurance or fatigability, and accounts for fluctuations in disease state. The QMG total score range is 0-39, with higher scores indicative of greater disease severity. A patient was considered a QMG responder during C1 if there was a reduction of ≥3-points on the QMG total score (compared to C1B) for ≥4 consecutive weeks with the first reduction occurring no later than 1 week after the last infusion of IMP in C1.

Time frame:
Baseline up to Day 63 (end of TC1)
Reported as:
Number · percentage of patients
Percentage of Quantitative Myasthenia Gravis (QMG) Responders During C1; Analyzed in the AChR-Ab Seropositive Population
percentage of patientsARGX-113Placebo
Percentage of Quantitative Myasthenia Gravis (QMG) Responders During C1; Analyzed in the AChR-Ab Seropositive Population63.114.1
Statistical analysis
  • ARGX-113 vs Placebo · Regression, Logistic · p = <0.0001 · Odds ratio (or): 10.842 · 95% CI 4.179 to 31.200
SecondaryPercentage of MG-ADL Responders During C1; Analyzed in the Overall Population

The percentage of MG-ADL responders during C1 in the overall population is reported for this secondary end point; percentage of MG-ADL responders during C1 in the AChR-Ab seropositive population is reported previously as a primary end point.

Time frame:
Baseline up to Day 63 (end of TC1)
Reported as:
Number · percentage of patients
Percentage of MG-ADL Responders During C1; Analyzed in the Overall Population
percentage of patientsARGX-113Placebo
Percentage of MG-ADL Responders During C1; Analyzed in the Overall Population67.937.3
Statistical analysis
  • ARGX-113 vs Placebo · Regression, Logistic · p = <0.0001 · Odds ratio (or): 3.699 · 95% CI 1.854 to 7.578
SecondaryPercentage of Time That Patients Had a Clinically Meaningful Improvement (CMI) in MG-ADL Total Score up to and Including Day 126; Analyzed in the AChR-Ab Seropositive Population

An MG-ADL CMI was defined as a reduction of ≥2 points on the total MG-ADL score compared to study entry baseline (SEB).

Time frame:
Baseline up to Day 126
Reported as:
Least squares mean · percentage of time
Percentage of Time That Patients Had a Clinically Meaningful Improvement (CMI) in MG-ADL Total Score up to and Including Day 126; Analyzed in the AChR-Ab Seropositive Population
percentage of timeARGX-113Placebo
Percentage of Time That Patients Had a Clinically Meaningful Improvement (CMI) in MG-ADL Total Score up to and Including Day 126; Analyzed in the AChR-Ab Seropositive Population48.714 ± 6.16326.649 ± 6.316
Statistical analysis
  • ARGX-113 vs Placebo · ANCOVA · p = 0.0001 · Least square means difference: 22.065 · 95% CI 10.949 to 33.181
SecondaryTime From Week 4 to Qualify for Retreatment; Analyzed in the AChR-Ab Seropositive Population

Time to qualify for retreatment was defined as time from the Week 4 assessment until the first visit with a \<2-point reduction compared to SEB in the MG-ADL total score and MG-ADL total score ≥5 points with \>50% of the total score attributable to nonocular symptoms.

Time frame:
Week 4 up to Day 182 (end of study [EoS])
Reported as:
Median · days
Time From Week 4 to Qualify for Retreatment; Analyzed in the AChR-Ab Seropositive Population
daysARGX-113Placebo
Time From Week 4 to Qualify for Retreatment; Analyzed in the AChR-Ab Seropositive Population35.0 (29.0 to 43.0)8.0 (1.0 to 30.0)
Statistical analysis
  • ARGX-113 vs Placebo · Log Rank · p = 0.2604
SecondaryPercentage of Early MG-ADL Responders During C1; Analyzed in the AChR-Ab Seropositive Population

A patient was considered an early MG-ADL responder during C1 if there was a reduction of ≥2 points on the MG-ADL total score (compared to C1B) for ≥4 consecutive weeks with the first reduction occurring no later than Week 2 (ie, after 1 or maximum 2 infusions of IMP in C1).

Time frame:
Baseline up to Day 63 (end of TC1)
Reported as:
Number · percentage of patients
Percentage of Early MG-ADL Responders During C1; Analyzed in the AChR-Ab Seropositive Population
percentage of patientsARGX-113Placebo
Percentage of Early MG-ADL Responders During C1; Analyzed in the AChR-Ab Seropositive Population56.925.0

Adverse events

Collected over Treatment-emergent adverse events were monitored from first administration of IMP on Day 1 until the EoS (up to a maximum of approximately 182 days).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
ARGX-1130/84 (0%)4/84 (4.8%)49/84 (58.3%)
Placebo0/83 (0%)7/83 (8.4%)48/83 (57.8%)
Most frequent serious events
Showing 10 of 12
Most frequent serious events
EventARGX-113Placebo
Myasthenia gravisNervous system disorders1/842/83
Atrial fibrillationCardiac disorders0/841/83
Myocardial ischaemiaCardiac disorders0/841/83
Therapeutic product ineffectiveGeneral disorders0/841/83
Upper respiratory tract infectionInfections and infestations0/841/83
Procedural painInjury, poisoning and procedural complications0/841/83
Spinal compression fractureInjury, poisoning and procedural complications0/841/83
Spinal ligament ossificationMusculoskeletal and connective tissue disorders0/841/83
Myasthenia gravis crisisNervous system disorders0/841/83
ThrombocytosisBlood and lymphatic system disorders1/840/83
Most frequent other events
Showing 10 of 12
Most frequent other events
EventARGX-113Placebo
HeadacheNervous system disorders24/8423/83
NasopharyngitisInfections and infestations10/8415/83
DiarrhoeaGastrointestinal disorders6/849/83
NauseaGastrointestinal disorders7/849/83
Upper respiratory tract infectionInfections and infestations9/844/83
Urinary tract infectionInfections and infestations8/844/83
Oropharyngeal painRespiratory, thoracic and mediastinal disorders3/847/83
HypertensionVascular disorders3/846/83
DizzinessNervous system disorders3/845/83
CoughRespiratory, thoracic and mediastinal disorders3/845/83

Baseline characteristics

All patients in the randomized population who received at least a partial dose of investigational medicinal product (IMP) were included in the baseline analysis.

Age, Continuous
Age, Continuous(years)ARGX-113PlaceboTotal
Mean45.9 ± 14.4148.2 ± 14.9747.0 ± 14.69
Age, Customized
Age, Customized(Participants)ARGX-113PlaceboTotal
18 - <65 years7369142
>= 65 years111425
Sex: Female, Male
Sex: Female, Male(Participants)ARGX-113PlaceboTotal
Female6355118
Male212849
Race (NIH/OMB)
Race (NIH/OMB)(Participants)ARGX-113PlaceboTotal
American Indian or Alaska Native202
Asian9716
Native Hawaiian or Other Pacific Islander000
Black or African American336
White6972141
More than one race101
Unknown or Not Reported011
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)ARGX-113PlaceboTotal
Japanese8715
Hispanic or Latino729
Not Hispanic or Latino6973142
Not Reported011
Concomitant gMG treatment
Concomitant gMG treatment(Participants)ARGX-113PlaceboTotal
Nonsteroidal Immunosuppressive Drugs (NSIDs)5151102
No NSIDs333265
AChR-Ab status
AChR-Ab status(Participants)ARGX-113PlaceboTotal
Positive6564129
Negative191938
08

Study locations

66 sites
  • Investigator Site 29
    Phoenix, Arizona 85018, United States
  • Investigator Site 66
    Carlsbad, California 92011, United States
  • Investigator Site 5
    Los Angeles, California 90033, United States
  • Investigator Site 49
    Los Angeles, California 90095, United States
  • Investigator Site 18
    Orange, California 92868, United States
  • Investigator Site 40
    Palo Alto, California 94304, United States
  • Investigator Site 59
    San Francisco, California 94115, United States
  • Investigator Site 58
    Aurora, Colorado 80045, United States
  • Investigator Site 34
    Jacksonville, Florida 32209, United States
  • Investigator Site 4
    Tampa, Florida 33612, United States
  • Investigator Site 30
    Springfield, Illinois 62702, United States
  • Investigator Site 25
    Iowa City, Iowa 52242, United States
  • Investigator Site 21
    Kansas City, Kansas 66160, United States
  • Investigator Site 27
    Boston, Massachusetts 02115, United States
  • Investigator Site 48
    Detroit, Michigan 48201, United States
  • Investigator Site 53
    Buffalo, New York 14202, United States
  • Investigator Site 3
    Chapel Hill, North Carolina 27599, United States
  • Investigator Site 20
    Cleveland, Ohio 44195, United States
  • Investigator Site 9
    Portland, Oregon 97239, United States
  • Investigator Site 17
    Charleston, South Carolina 29425, United States
  • Investigator Site
    Cordova, Tennessee 38018, United States
  • Investigator Site 44
    Houston, Texas 77030, United States
  • Investigator Site 6
    San Antonio, Texas 78229, United States
  • Investigator Site 2
    Charlottesville, Virginia 22908, United States
  • Investigator Site 16
    Seattle, Washington 98195, United States
  • Investigator Site 11
    Edegem, 2650, Belgium
  • Investigator Site 8
    Ghent, 9000, Belgium
  • Investigator Site 38
    Edmonton, Alberta T6G 2G3, Canada
  • Investigator Site 24
    Toronto, Ontario M5G 2C4, Canada
  • Investigator Site 22
    Montréal, Quebec H3A 2B4, Canada
  • Investigator Site 32
    Brno, 62500, Czechia
  • Investigator Site 35
    Ostrava-Poruba, 70852, Czechia
  • Investigator Site 51
    Praha 2, 128 00, Czechia
  • Investigator Site 36
    Aarhus, 8200, Denmark
  • Investigator Site 15
    Copenhagen, 2100, Denmark
  • Investigator Site 13
    Bordeaux Cedex, 33076, France
  • Investigator Site 52
    Marseille, 13385, France
  • Investigator Site 46
    Tbilisi, 0112, Georgia
  • Investigator Site 45
    Tbilisi, 0114, Georgia
  • Investigator Site 47
    Tbilisi, 0114, Georgia
  • Investigator Site 33
    Berlin, 10117, Germany
  • Investigator Site 55
    Budapest, 1204, Hungary
  • Investigator Site 54
    Szeged, 6725, Hungary
  • Investigator Site 10
    Milano, 20133, Italy
  • Investigator Site 12
    Napoli, 80131, Italy
  • Investigator Site 42
    Chiba-shi, Chiba 260-8677, Japan
  • Investigator Site 26
    Sapporo, Hokkaido 0608543, Japan
  • Investigator Site 19
    Hanamaki, Iwate 025-0075, Japan
  • Investigator Site 43
    Sendai, Miyagi 983-8520, Japan
  • Investigator Site 50
    Suita, Osaka 565-0871, Japan
  • Investigator Site 28
    Ōsaka-sayama, Osaka 5898511, Japan
  • Investigator Site 31
    Meguro, Tokyo 1538515, Japan
  • Investigator Site 41
    Minato-Ku, Tokyo 108-8329, Japan
  • Investigator Site 39
    Shinjuku-Ku, Tokyo 160-0023, Japan
  • Investigator Site 37
    Leiden, 2333 ZA, Netherlands
  • Investigator Site 7
    Gdańsk, 80-952, Poland
  • Investigator Site 57
    Katowice, 40-123, Poland
  • Investigator Site 14
    Kraków, 31-505, Poland
  • Investigator Site 23
    Warszawa, 02-097, Poland
  • Investigator Site 64
    Krasnoyarsk, 660037, Russian Federation
  • Investigator Site 62
    Nizhny Novgorod, 603126, Russian Federation
  • Investigator Site 65
    Novosibirsk, 630087, Russian Federation
  • Investigator Site 60
    Samara, 443095, Russian Federation
  • Investigator Site 61
    Belgrade, 11000, Serbia
  • Investigator Site 63
    Edgbaston, B15 2TH, United Kingdom
  • Investigator Site 56
    Liverpool, L9 7LJ, United Kingdom
09

References and documents

Publications

  • Howard JF Jr, Bril V, Vu T, Karam C, Peric S, Margania T, Murai H, Bilinska M, Shakarishvili R, Smilowski M, Guglietta A, Ulrichts P, Vangeneugden T, Utsugisawa K, Verschuuren J, Mantegazza R; ADAPT Investigator Study Group. Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial. Lancet Neurol. 2021 Jul;20(7):526-536. doi: 10.1016/S1474-4422(21)00159-9. Erratum In: Lancet Neurol. 2021 Aug;20(8):e5. doi: 10.1016/S1474-4422(21)00216-7. PubMed 34146511 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2018 to primary completion in Apr 2020, 19 months.

Results were first posted in Feb 2022, 1 year 10 months after primary completion. A results delay was requested in Mar 2021.

Of 43 industry-sponsored phase 3 interventional studies under Myasthenia Gravis, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 39. This study's 19 months is below that.

Counting every sponsor, half of 52 studies reached it within 30 months; a quarter within 20 and three quarters within 43.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 6, 2018
First posted
Sep 13, 2018
StartActual
Aug 22, 2018
Primary completionActual
Apr 6, 2020
CompletionActual
Apr 6, 2020
Results delay requested
Mar 15, 2021
Results first posted
Feb 8, 2022
Last update
Feb 8, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 8, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03669588
Lead sponsor
argenx
Responsible party
Sponsor
First posted
Sep 13, 2018
Start date
Aug 22, 2018
Primary completion
Apr 6, 2020
Completion
Apr 6, 2020
Results posted
Feb 8, 2022
Last update
Feb 8, 2022

Study contacts

Antonio Guglietta, MD
study director · argenx

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Efgartigimod alfa

Start the discussion